Labedipinedilol-C: A third-generation dihydropyridine-type calcium channel antagonist displaying K+ channel opening, NO-dependent and adrenergic antagonist activities

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 2, 2005, Pages 130-140

  Yeh, Jwu Lai ^a   Liou, Shu Fen ^a   Liang, Jhy Chong ^b   Lee, Chih Hsiung ^a   Chiu, Chaw Chi ^a   Lin, Young Tso ^a   Chen, Ing Jun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHIN MIN INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

adrenoceptor blockade; Ca2+ channel blockade; K+ channels; Nitric oxide synthase; Vasorelaxant effect

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; APAMIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHLORIDE; CHARYBDOTOXIN; DIHYDROPYRIDINE DERIVATIVE; GLIBENCLAMIDE; GUANYLATE CYCLASE INHIBITOR; ISOPRENALINE; LABEDIPINEDILOL C; LACIDIPINE; LERCANIDIPINE; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; NITRENDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM ION; PRAZOSIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VANYLIDILOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; GUINEA PIG; HEART RATE; HUMAN; HUMAN CELL; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; ISOLATED ORGAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; UMBILICAL VEIN; VASODILATATION;

ADRENERGIC ANTAGONISTS; ANIMALS; AORTA; BINDING, COMPETITIVE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELL LINE; DIHYDROPYRIDINES; GUINEA PIGS; HEART RATE; HUMANS; HYPERTENSION; ION CHANNEL GATING; NITRIC OXIDE; PIPERAZINES; POTASSIUM CHANNELS; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA; TRACHEA; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 23044433930     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000167016.61845.c8     Document Type: Article

References (32)

1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-625.
2. Lee CR, Bryson HM. Lacidipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs. 1994;48:274-296.
3. Motomura S, Wu ZJ, Hashimoto K. Lacidipine, a new long-acting dihydropyridine calcium antagonist, has high vascular selectivity agonist all intracardiac variables. Heart Vessel. 1994;8:16-22.
4. Gasser R, Koppel H, Klein W. Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension. J Clin Bas Cardiol. 1999; 2:169-174.
5. Massart PE, Donckier J, Kyselovic J, et al. Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. Hypertension. 1999;34:1197-1201.
6. Hernandez RH, Armas-Hernandez MJ, Velasco M, et al. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther. 2003;10:409-414.
7. 1- adrenoceptor-blocking activity. Arch Int Pharmacodyn Ther. 1994;328:213-224.
8. 1-adrenoceptor blocking agent. Arch Int Pharmacodyn Ther. 1993;321: 30-40.
9. Liang JC, Yeh JL, Chiang LC, et al. Labedipinedilol-A: Avanilloid-based α/β-adrenoceptor blocker with calcium entry blocking and long acting anti-hypertensive properties. Drug Dev Res. 2000;49:94-108.
10. Liang JC, Yeh JL, Wang CS, et al. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display α/β-adrenoceptor antagonist and long-acting antihypertensive activities. Bioorg Med Chem. 2002;10:719-730.
11. Yeh JL, Liou SF, Liang JC, et al. Vanidipinedilol: A vanilloid-based β-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities. J Cardiovasc Pharmacol. 2000;35:51-63.
12. Yeh JL, Tsai CH, Liang JC, et al. Third-generation dihydropyridine-type calcium channel blocker labedipinedilol-B displays α/β-adrenoceptor blocking activities. Drug Dev Res. 2001;52:462-474.
13. Liou SF, Yeh JL, Liang JC, et al. Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J Cardiovasc Pharmacol. 2004;44: 539-551.
14. + channels opening-associated vasorelaxant activities. Pharmacology. 2004;70:140-151.
15. Berkels R, Egink G, Marsen TA, et al. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240-245.
16. Berkels R, Taubert D, Rosenkranz A, et al. Vascular protective effects of dihydropyridine calcium antagonists. Pharmacology. 2003;69:171-176.
17. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535-560.
18. Archer SL. Potassium channels and erectile dysfunction. Vasc Pharmacol. 2002;38:61-71.
19. + channels in pulmonary hypertension. Vasc Pharmacol. 2002;38:25-33.
20. Yeh JL, Wu JR, Chiu CC, et al. Vanillylamide-based propanolamine derivative displays α/β-adrenoceptor blocking and vasodilating properties. J Cardiovasc Pharmacol. 2002;39:803-813.
21. Yeh JL, Yang TH, Liang JC, et al. Isoeugenodilol: A vasorelaxant α/β-adrenoceptor blocker with antioxidant activities. Drug Dev Res. 2000;51:29-42.
22. 1-adrenoceptor antagonist with α-adrenoceptor blocking and potassium channel opening activities. Drug Dev Res. 2002;55:104-117.
23. Lo YC, Hsiao HC, Wu DC, et al. A novel capsaicin derivative VOA induced relaxation in rat mesenteric and aortic arteries. Involvement of CGRP, NO, cGMP, and endothelium-dependent activities. J Cardiovasc Pharmacol. 2003;42:511-520.
24. Chen IJ, Yeh JL, Liou SJ, et al. Guaiacoxypropanolamine derivatives of capsaicin: A new family of β-adrenoceptor blockers with intrinsic cardiotonic properties. J Med Chem. 1994;37:938-943.
25. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986;38:321-416.
26. Oparil S, Calhoun DA. The calcium antagonists in the 1990s. An overview. Am J Hypertens. 1991;4:396S-405S.
27. Coburn RF. Couping mechanisms in airway smooth muscle. Am J Physiol. 1990;267:L119-L133.
28. Somlyo AP, Himpens B. Cell calcium and its regulation in smooth muscle. FASEB J. 1989;3:2266-2267.
29. + channels opening activities in rat aortic smooth muscle. Br J Pharmacol. 2001;134:265-274.
30. Koh SD, Campbell JD, Carl A, et al. Nitric oxide activates multiple potassium channels in canine colonic smooth muscle. J Physiol. 1995;489:735-743.
31. + channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: Relative efficacy and interactions between both pathways. Br J Pharmacol. 1998; 123:847-854.
32. + channels in cultured vascular smooth muscle. Circ Res. 1993;74:471-476.